HERON THERAPEUTICS, INC. /DE/ (HRTX): Submission of Matters to a Vote of Security Holders
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0000818033 false 0000818033 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
How this was made
The 30-second read
Why it matters
Confirms shareholder approval of (i) seven director nominees, (ii) Withum Smith+Brown as independent auditor for FY ending Dec. 31, 2026, (iii) nonbinding advisory executive compensation, (iv) amendments to the 2007 equity incentive plan and 1997 employee stock purchase plan to increase authorized shares, and (v) adoption of a Tax Benefits Preservation Plan on a nonbinding advisory basis.
Market read
Useful for tracking governance and future equity issuance capacity, but not a new earnings/clinical/regulatory catalyst.
What to watch
The tax benefits preservation plan approval could be relevant if investors are tracking NOL/ownership-change protection, but the filing does not quantify the plan’s terms or expected impact.
Background
Form 8-K Item 5.07 discloses the results of shareholder votes at the company’s annual meeting.
Ticker impact
Heron Therapeutics reported 2026 annual meeting voting results, including director elections, auditor ratification, and equity plan share increases.
Likely limited near-term impact; any effect would be indirect via shareholder approval of equity/tax plan mechanics.
An 8-K Item 5.07 typically confirms outcomes of previously proposed matters; it can matter for dilution/tax-asset preservation expectations but provides no new operational or financial guidance.
Market effects
Minimal; this is company-specific governance and equity-plan authorization rather than a sector catalyst.
None indicated; Nasdaq-listed small/mid-cap governance update.
None indicated.
Counterpoint
Even without new fundamentals, equity-plan share increases can affect perceived dilution over time; traders may still reprice risk if the market focuses on future issuance capacity.
Key entities
- companyHeron Therapeutics, Inc.
Nasdaq-listed issuer filing the 8-K with annual meeting voting outcomes.
- auditorWithum Smith+Brown, PC
Independent registered public accounting firm ratified for FY ending Dec. 31, 2026.
- corporate_actionTax Benefits Preservation Plan
Shareholder-advisory ratification of adoption intended to help preserve tax benefits.
